Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 07, 2013 16:01 ET | Source: TESARO, Inc.

TESARO Announces Third-Quarter 2013 Operating Results

Top-Line Results Expected to be Announced at Year-End 2013 from Two Phase 3 Trials of Oral Rolapitant Patient Enrollment in the Third Phase 3 Trial of Oral Rolapitant Expected to Conclude at...
October 24, 2013 07:01 ET | Source: TESARO, Inc.

TESARO to Announce Third Quarter 2013 Financial Results on November 7, 2013

WALTHAM, Mass., Oct. 24, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its third quarter 2013 financial results on Thursday, November 7, 2013, after the close of the U.S. financial...
September 30, 2013 08:01 ET | Source: TESARO, Inc.

TESARO Announces Initiation of Rolapitant IV Clinical Program

WALTHAM, Mass., Sept. 30, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that an open label, dose-finding and escalation study has...
September 29, 2013 08:01 ET | Source: TESARO, Inc.

TESARO Describes Initial Phase 1 Clinical Data for TSR-011 Presented at the European Cancer Congress 2013

TSR-011 Identified as a Potent Dual Inhibitor of ALK and TRK Kinases Preliminary Clinical Activity Demonstrated in Patients with Several Tumors, Including ALK-Positive NSCLC Patients...
August 30, 2013 08:01 ET | Source: TESARO, Inc.

TESARO to Participate in Several Upcoming Investor Conferences

WALTHAM, Mass., Aug. 30, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, announced that Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, Ph.D.,...
July 25, 2013 16:01 ET | Source: TESARO, Inc.

TESARO Announces Second-Quarter 2013 Operating Results

Top-Line Results from Rolapitant Phase 3 Program to be Announced by Year-End 2013 Patient Enrollment Ongoing in Phase 3 Trial of Niraparib in Ovarian Cancer Phase 3 Trial of Niraparib in...
July 23, 2013 07:01 ET | Source: TESARO, Inc.

TESARO Initiates Phase 3 Trial of Niraparib for Treatment of Patients With Ovarian Cancer

WALTHAM, Mass., July 23, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that it has initiated patient enrollment in a Phase 3 trial...
July 18, 2013 07:01 ET | Source: TESARO, Inc.

TESARO to Announce Second Quarter 2013 Financial Results on July 25, 2013

WALTHAM, Mass., July 18, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its second quarter 2013 financial results on Thursday, July 25, 2013, after the close of the U.S. financial...
July 02, 2013 16:01 ET | Source: TESARO, Inc.

TESARO to Present at the 8th Annual JMP Securities Healthcare Conference

WALTHAM, Mass., July 2, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, Chief Executive Officer, will present at the 8th Annual JMP Securities 2013 Healthcare...
June 28, 2013 07:01 ET | Source: TESARO, Inc.

TESARO Announces Presentation of Rolapitant Pharmacokinetic (PK) Data at the MASCC/ISOO International Symposium

PK Data from Drug-Drug Interaction Study Describes Lack of CYP3A4 Interactions BERLIN, June 28, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical...